Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies.

Adriano Basso DiasSangeet GhaiClaudia OrtegaSeyed Ali MirshahvaladNathan PerlisAlejandro BerlinLisa AveryPatrick Veit-HaibachTheodorus van der KwastUr Metser

Published in: Clinical nuclear medicine (2023)

18F-DCFPyL PET/MRI excluded nearly 30% of patients with low-/intermediate-risk PCa from FT, with a potential role in decreasing selection failure. Compared with mpMRI, PET/MRI had a higher sensitivity for detecting csPCa in men who were candidates for FT.ClinicalTrials.gov identifier NCT03149861.

Keyphrases

pet ct
contrast enhanced
prostate cancer
computed tomography
magnetic resonance imaging
positron emission tomography
diffusion weighted imaging
pet imaging
middle aged
radical prostatectomy